This remarkable activity of tetravalent bsAb CD73xEpCAM is most likely attributable to its enhanced avidity for binding to EpCAM exposed on the cancer cell surface and the concurrent blocking of the CD73 activity. This evidence concerns the gene EPCAM and cancer.